AU2018309718B2 - Antifungal agents with enhanced activity in acidic pH - Google Patents

Antifungal agents with enhanced activity in acidic pH Download PDF

Info

Publication number
AU2018309718B2
AU2018309718B2 AU2018309718A AU2018309718A AU2018309718B2 AU 2018309718 B2 AU2018309718 B2 AU 2018309718B2 AU 2018309718 A AU2018309718 A AU 2018309718A AU 2018309718 A AU2018309718 A AU 2018309718A AU 2018309718 B2 AU2018309718 B2 AU 2018309718B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018309718A
Other languages
English (en)
Other versions
AU2018309718A1 (en
Inventor
David A. ANGULO GONZALEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
SCYNEXIS Inc
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018309718(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SCYNEXIS Inc, Scynexis Inc filed Critical SCYNEXIS Inc
Publication of AU2018309718A1 publication Critical patent/AU2018309718A1/en
Application granted granted Critical
Publication of AU2018309718B2 publication Critical patent/AU2018309718B2/en
Priority to AU2024227501A priority Critical patent/AU2024227501A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018309718A 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic pH Active AU2018309718B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024227501A AU2024227501A1 (en) 2017-08-04 2024-10-21 Antifungal agents with enhanced activity in acidic pH

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541370P 2017-08-04 2017-08-04
US62/541,370 2017-08-04
PCT/US2018/044619 WO2019028034A1 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic ph

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024227501A Division AU2024227501A1 (en) 2017-08-04 2024-10-21 Antifungal agents with enhanced activity in acidic pH

Publications (2)

Publication Number Publication Date
AU2018309718A1 AU2018309718A1 (en) 2020-02-27
AU2018309718B2 true AU2018309718B2 (en) 2024-07-25

Family

ID=63209698

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018309718A Active AU2018309718B2 (en) 2017-08-04 2018-07-31 Antifungal agents with enhanced activity in acidic pH
AU2024227501A Pending AU2024227501A1 (en) 2017-08-04 2024-10-21 Antifungal agents with enhanced activity in acidic pH

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024227501A Pending AU2024227501A1 (en) 2017-08-04 2024-10-21 Antifungal agents with enhanced activity in acidic pH

Country Status (26)

Country Link
US (3) US11534433B2 (cg-RX-API-DMAC7.html)
EP (3) EP4169514B1 (cg-RX-API-DMAC7.html)
JP (1) JP7214714B2 (cg-RX-API-DMAC7.html)
KR (1) KR102807716B1 (cg-RX-API-DMAC7.html)
CN (2) CN118542868A (cg-RX-API-DMAC7.html)
AU (2) AU2018309718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002290A2 (cg-RX-API-DMAC7.html)
CA (1) CA3071940A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125690T1 (cg-RX-API-DMAC7.html)
DK (1) DK3661503T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090445A1 (cg-RX-API-DMAC7.html)
ES (2) ES2932658T3 (cg-RX-API-DMAC7.html)
FI (1) FI3661503T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221414T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060508T2 (cg-RX-API-DMAC7.html)
LT (1) LT3661503T (cg-RX-API-DMAC7.html)
MA (1) MA49751B1 (cg-RX-API-DMAC7.html)
MD (1) MD3661503T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020001399A (cg-RX-API-DMAC7.html)
PL (1) PL3661503T3 (cg-RX-API-DMAC7.html)
PT (1) PT3661503T (cg-RX-API-DMAC7.html)
RS (1) RS63746B1 (cg-RX-API-DMAC7.html)
SI (1) SI3661503T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200461T1 (cg-RX-API-DMAC7.html)
TW (1) TWI805600B (cg-RX-API-DMAC7.html)
WO (1) WO2019028034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228036B2 (en) * 2019-02-27 2025-08-07 Scynexis, Inc. Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
PT3247711T (pt) 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANBY C.S. et al. "Effect of pH on in vitro susceptibility of Candida glabrata and Candida albicans to 11 antifungal agents and implications for clinical use", ANTIMICROBROBIAL AGENTS && CHEMOTHERAPY (2012), vol. 56, pages 1403-1406 *
HELOU, S. 25 April 2017. Retrieved from the Internet: *
SCYNEXIS: 5 October 2016, Retrieved from the Internet *

Also Published As

Publication number Publication date
US20200390751A1 (en) 2020-12-17
CN118542868A (zh) 2024-08-27
EP4169514B1 (en) 2026-01-28
SMT202200461T1 (it) 2023-01-13
MD3661503T2 (ro) 2023-01-31
KR20200044823A (ko) 2020-04-29
CA3071940A1 (en) 2019-02-07
AU2024227501A1 (en) 2024-11-07
TWI805600B (zh) 2023-06-21
BR112020002290A2 (pt) 2020-09-08
US20260000656A1 (en) 2026-01-01
HUE060508T2 (hu) 2023-03-28
JP7214714B2 (ja) 2023-01-30
HRP20221414T1 (hr) 2023-01-20
PL3661503T3 (pl) 2023-01-09
CN111093655A (zh) 2020-05-01
AU2018309718A1 (en) 2020-02-27
SI3661503T1 (sl) 2023-01-31
MX2020001399A (es) 2020-08-06
MA49751B1 (fr) 2022-12-30
TW201919476A (zh) 2019-06-01
LT3661503T (lt) 2022-12-12
WO2019028034A1 (en) 2019-02-07
PT3661503T (pt) 2022-12-13
RS63746B1 (sr) 2022-12-30
EP4169514A1 (en) 2023-04-26
EP3661503A1 (en) 2020-06-10
JP2020529999A (ja) 2020-10-15
DK3661503T3 (da) 2022-12-12
FI3661503T3 (fi) 2022-12-15
MA49751A (fr) 2020-06-10
US20230364067A1 (en) 2023-11-16
KR102807716B1 (ko) 2025-05-13
CY1125690T1 (el) 2026-02-25
EP3661503B1 (en) 2022-09-07
EP4732902A3 (en) 2026-07-22
US11534433B2 (en) 2022-12-27
ES2932658T3 (es) 2023-01-23
EA202090445A1 (ru) 2020-06-23
EP4732902A2 (en) 2026-04-29
EP4169514C0 (en) 2026-01-28
ES3068719T3 (en) 2026-06-02

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
TW201842915A (zh) 組合使用的抗真菌劑
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
TWI910099B (zh) 用於治療或預防肺囊蟲屬肺炎之三萜類抗真菌劑
HK40109129A (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)